Sensei biotherapeutics reports full year 2023 financial results and recent business highlights

- updated dose escalation data from sns-101 clinical study supports favorable and potentially best-in-class safety and pk profile both as monotherapy and in combination with pd-1 blockade -
SNSE Ratings Summary
SNSE Quant Ranking